The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis
Abstract
OBJECTIVES: Although linezolid has good in vitro activity against Mycobacterium tuberculosis, its long-term use in the treatment of multidrug-resistant tuberculosis (MDR-TB) may be limited by its cost and serious adverse reactions. We therefore evaluated the efficacy and tolerability of a reduced dose of linezolid, in combination with other anti-TB drugs, in patients with intractable or extensive MDR-TB. METHODS: MDR-TB patients unresponsive to at least three cycles of treatment were treated with daily-half doses of linezolid (600 mg once per day) plus at least four companion drugs. RESULTS: As of March 2006, eight patients, all HIV-negative, had been treated with linezolid for 3-18 months. Cultures became negative in all patients in an average of 82 days. Four patients developed peripheral neuropathy, two developed optic neuropathy and one developed anaemia. Although optic neuropathy resolved after cessation of linezolid therapy, peripheral neuropathy continued. One patient completed 18 months of linezolid therapy. Two patients, who have taken linezolid for 15-17 months, are still on treatment and remain in culture conversion. Three patients stopped linezolid after 7-9 months, two because of side effects and one for economic reasons, but remain on treatment with other second-line drugs with culture conversion. Two patients died from severe respiratory failure, but both previously had shown culture conversion. CONCLUSIONS: Although daily-half doses of linezolid were effective in patients with intractable or extensive MDR-TB, this dosage regimen did not reduce long-term use-related side effects, such as peripheral and optic neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“diaryquinolones) in the same class of agent.(2,3) Many patients, however, have shown cross-resistance within this class, suggesting that previous administration of older fluoroquinolones may have a negative impact on the effectiveness of new compounds.”
Background
Cited by
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
Caminero, J. A., Sotgiu, G., Zumla, A., & Migliori, G. B. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70139-0 · Cited by 574
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Lee, M., Lee, J., Carroll, M. W., Choi, H., Min, S., Song, T., Via, L. E., Goldfeder, L. C., Kang, E., Jin, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201964 · Cited by 560
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Alsultan, A., & Peloquin, C. A. (2014) · Drugs · doi:10.1007/s40265-014-0222-8 · Cited by 444
Sotgiu, G., Centis, R., D'Ambrosio, L., Alffenaar, J.-W. C., Anger, H. A., Caminero, J. A., Castiglia, P., De Lorenzo, S., Ferrara, G., Koh, W.-J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00022912 · Cited by 416
Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis
Sacchettini, J. C., Rubin, E. J., & Freundlich, J. S. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1816 · Cited by 256
Metadata
- Authors
- Park, I.-N.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07-01
- Volume
- 58
- Issue
- 3
- Pages
- 701-704
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2130503164
- Cited by
- 161
- References
- 1
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. https://app.cochat.ai/papers/10.1093/jac/dkl298
- The paper
- Park, I.-N. (2006). Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkl298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.